Last reviewed · How we verify

NCT06166095

Dose-Response Effect Exercise and Depression

Completed NA Last updated 27 March 2025
What this trial tests

NA trial testing high-dose in Depression in 48 participants. Completed in 1 December 2024.

Timeline
1 July 2023
Primary endpoint
1 December 2024
1 December 2024

Quick facts

Lead sponsorUniversity of Central Florida
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment48
Start date1 July 2023
Primary completion1 December 2024
Estimated completion1 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Central Florida

Who can join

Adults 18 to 25, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to address gaps in the literature by evaluating the objectively measured dose-response relationship between exercise and depression symptoms; examining changes in resting (Brain-derived Neurotrophic Factor) BDNF from baseline to week 10 of an exercise intervention; and assessing varying exercise intensities on enjoyment, affect, and health-related quality of life in sedentary young adult college students.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

Other University of Central Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06166095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing